Trial Profile

A Phase II Randomized Study Evaluating Nintedanib versus Placebo as Prophylaxis against Radiation Pneumonitis in Patients with Unresectable NSCLC Undergoing ChemoRadiation Therapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nintedanib (Primary) ; Durvalumab
Indications Carcinoma; Non-small cell lung cancer; Pneumonitis
Focus Therapeutic Use

Most Recent Events

01 Mar 2021 The protocol was amended to only enroll patients with nonsquamous histology, according to Results published in the Journal of Thoracic Oncology
01 Mar 2021 Results published in the Journal of Thoracic Oncology
23 Mar 2020 Status changed from completed to discontinued.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com